<DOC>
	<DOC>NCT02318914</DOC>
	<brief_summary>The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers</brief_summary>
	<brief_title>A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>Individuals who participated in a previous study of gevokizumab in PG A clinical diagnosis of classic pyoderma gangrenosum Contraceptive measures adequate to prevent pregnancy during the study Clinical evidence of acutely infected pyoderma gangrenosum History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent or chronic systemic infections Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Classic Pyoderma Gangrenosum</keyword>
</DOC>